Vetafarm Pty Ltd, Wagga Wagga, NSW, 2650, Australia.
Centre for Chronic Disease, College of Health & Biomedicine, Victoria University, Melbourne, Australia.
Immunotherapy. 2018 Feb 1;10(4):283-298. doi: 10.2217/imt-2017-0123.
Prostate cancer (PC) is a common malignancy among elderly males and is noncurable once it becomes metastatic. In recent years, a number of antigen-delivery systems have emerged as viable and promising immunotherapeutic agents against PC. The approval of sipuleucel-T by the US FDA for the treatment of males with asymptomatic or minimally symptomatic castrate resistant PC was a landmark in cancer immunotherapy, making this the first approved immunotherapeutic. A number of vaccines are under clinical investigation, each having its own set of advantages and disadvantages. Here, we discuss the basic technologies underlying these different delivery modes, we discuss the completed and current human clinical trials, as well as the use of vaccines in combination with immune checkpoint inhibitors.
前列腺癌（PC）是老年男性常见的恶性肿瘤，一旦发生转移就无法治愈。近年来，许多抗原递呈系统已成为针对 PC 的可行且有前途的免疫治疗药物。美国 FDA 批准 sipuleucel-T 用于治疗无症状或轻度症状去势抵抗性 PC 的男性，这是癌症免疫治疗的一个里程碑，使其成为第一个获得批准的免疫治疗药物。许多疫苗正在进行临床研究，每种疫苗都有其自身的优缺点。在这里，我们讨论了这些不同传递模式所基于的基本技术，讨论了已完成和当前的人体临床试验，以及疫苗与免疫检查点抑制剂联合使用。
